Erlotinib News and Research RSS Feed - Erlotinib News and Research

Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Epidermal growth factor receptor–tyrosine kinase inhibitors appear to significantly reduce the efficacy of subsequent chemotherapy in patients with EGFR-mutated non-small-cell lung cancer, Chinese researchers report. [More]
Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers. [More]
Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients. [More]
Antacids linked to reduced erlotinib efficacy

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show. [More]
Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest. [More]
Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show. [More]

Lung Cancer Alliance praises NCI's new ALCHEMIST trial

Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed. [More]

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations. [More]
CRIPTO1 role in TKI resistance elucidated

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. [More]
Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests. [More]
Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology, Inc. announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type. [More]
Survival differences after docetaxel, erlotinib are EGFR dependent

Survival differences after docetaxel, erlotinib are EGFR dependent

Results from the DELTA trial indicate no significant differences in progression-free or overall survival after treatment with docetaxel versus erlotinib in non-small-cell lung cancer patients unselected for their epidermal growth factor receptor mutation status. [More]
Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]